Bioactive small-molecule inhibitors represent a treasure chest for future drugs. In vitro high-throughput screening is a common approach to identify the small-molecule inhibitors that bind tightly to purified targets. Here, we investigate the inhibitor-target binding/unbinding kinetics in E. coli cells using a benzimidazole-derivative DNA inhibitor as a model system. We find that its unbinding rate is not constant but depends on cell growth rate. This dependence is mediated by the cellular activity, forming a feedback loop with the inhibitor's activity. In accordance with this feedback, we find cell-to-cell heterogeneity in inhibitor-target interaction, leading to co-existence of two distinct subpopulations: actively growing cells that dissociate the inhibitors from the targets and non-growing cells that do not. We find similar heterogeneity for other clinical DNA inhibitors. Our studies reveal a mechanism that couples inhibitor-target kinetics to cell physiology and demonstrate the significant effect of this coupling on drug efficacy.
Keyphrases
- small molecule
- induced apoptosis
- single cell
- escherichia coli
- cell cycle arrest
- endoplasmic reticulum stress
- cell therapy
- oxidative stress
- circulating tumor
- emergency department
- single molecule
- protein protein
- cell free
- molecular docking
- staphylococcus aureus
- mesenchymal stem cells
- cell proliferation
- pseudomonas aeruginosa
- current status
- circulating tumor cells
- pi k akt
- case control
- tissue engineering